News

MEJM: Two women were infected after receiving mRNA COVID-19 vaccine

MEJM: Two women were infected after receiving mRNA COVID-19 vaccine. 2 cases of “breakthrough infection” reported: Two women contracted COVID-19 after receiving mRNA vaccine.

A new study in the “New England Journal of Medicine” reports two cases of “breakthrough infection”, confirming scientists’ concerns that certain new coronavirus variants can evade mRNA vaccines.

However, people have never expected that vaccination can prevent infection 100%, and these results have not disrupted the vaccination work in any way. It just makes this matter more urgent.

The corresponding author of the study and a biochemist at Rockefeller University, Ezgi Hacisuleyman, said: “Our observations underscore the importance of continuous competition between immunity and natural selection of potential virus escape mutants.

Two women who were fully vaccinated with the new coronavirus (the first dose was the Pfizer/BioNtech vaccine, the second dose was the Moderna vaccine) were again diagnosed with the new coronavirus.

The good news is that their condition is relatively mild, so the vaccine may still protect them. However, it is not clear whether people who are fully vaccinated will be infected with severe new coronavirus pneumonia.

Case 2 is a 65-year-old female who tested positive for the virus 36 days after receiving the second dose of vaccine. However, case 1 tested positive for the virus 36 days after the second dose of vaccine. Therefore, the researchers stated that the possibility of her being infected before the second vaccination cannot be ruled out.

This study monitored the employees and students of Rockefeller University in the United States and produced samples representing more than 400 vaccinated employees and nearly 1,500 unvaccinated volunteers. Since last fall, researchers have sampled their saliva every week.

The researchers wrote: “Both of these patients may have developed an effective immune response to the vaccine. Our observations describe real cases of vaccine breakthroughs as clinical symptoms.”

In this study, Hacisuleyman and his team studied the genetic sequence of the variant strain and found that the strain of case 1 contained both the B.1.1.7 strain from the United Kingdom and the B.1.526 strain from New York. Researchers believe that this may be the result of the recombination of the two strains.

When two different strains of the same virus infect the same host cell, genetic recombination of the virus occurs. In this shared environment, they can exchange genes and copy at the same time to produce the next generation. This is a way for viruses to change themselves, making it more difficult for our bodies to recognize and control them.

Another possibility of mutation combination seen in the strain of case 1 is convergent evolution. This means that selective pressure from the environment causes the same mutation to develop more than once in isolation.
Previous studies have shown that the South African strain B.1.351 seems to be able to evade the neutralizing antibodies produced by the human body against vaccines and previous strain infections. Major pharmaceutical companies are already racing to develop next-generation vaccines to combat these new variants.

This rapidly changing situation is why medical experts urge us to focus on mRNA vaccines. They are the fastest response to new variants, because apart from RNA recoding, everything else related to the new vaccine will remain unchanged.

These results show how important it is to vaccinate as many people in the world as possible in the shortest time we can achieve in order to prevent more breakthrough infections.

(source:internet, reference only)

Disclaimer of medicaltrend.org